R. A. SWEET, M.D.; JAMES L. MALES, M.D.; ALAN J. HAMSTRA; HECTOR F. DeLUCA, Ph.D.
This content is PDF only. Please click on the PDF icon to access.
Hypophosphatemic osteomalacia has been described in conjunction with a variety of mesenchymal tumors (1-3). This condition has also been called "oncogenic osteomalacia" and is associated with muscular weakness, hypophosphatemia, and bone roentgenograms compatible with osteomalacia or rickets. Resection of a localized tumor resolves the hypophosphatemia and osteomalacia. Drezner and Feinglos (4) noted that the hypophosphatemia and osteomalacia were associated with decreased levels of 1,25 dihydroxycholecalciferol (1,25(OH)2D3) which returned to normal after resection of a giant cell tumor of bone. These authors concluded that the low levels of 1,25(OH)2D3 were secondary to a tumor-produced factor that interfered with renal 25-hydroxycholecalciferol-1-hydroxylase activity.
SWEET RA, MALES JL, HAMSTRA AJ, DeLUCA HF. Vitamin D Metabolite Levels in Oncogenic Osteomalacia. Ann Intern Med. ;93:279–280. doi: 10.7326/0003-4819-93-2-279
Download citation file:
© 2019
Published: Ann Intern Med. 1980;93(2):279-280.
DOI: 10.7326/0003-4819-93-2-279
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by: